Anti-sulfatide IgM antibodies in peripheral neuropathy: To test or not to test?

C. Giannotta, D. Di Pietro, F. Gallia, E. Nobile-Orazio

Research output: Contribution to journalArticle

Abstract

Background and purpose: Anti-sulfatide immunoglobulin M (IgM) antibodies have been associated with different forms of neuropathies but their diagnostic role in neuropathy remains unclear. Methods: The clinical association of increased titers of anti-sulfatide IgM antibodies in 570 patients with neuropathy and related disorders examined in our laboratory since 2004 was reviewed. Sera were tested by enzyme-linked immunosorbent assay at the initial serum dilution of 1:32 000 and titrated by serial two-fold dilution. In all positive patients IgM antibodies to myelin-associated glycoprotein (MAG) were also measured by western blot. Results: High titers of anti-sulfatide antibodies were found in 39 patients including 33 (85%) who also had anti-MAG IgM. Six patients did not have anti-MAG IgM including five in whom moderately increased anti-sulfatide titers were associated with different forms of neuropathy. One patient with a demyelinating neuropathy and IgM monoclonal gammopathy had markedly increased anti-sulfatide titers (1:256 000). Conclusions: Increased titers of anti-sulfatide IgM antibodies are not infrequent in patients with neuropathy where they are often associated with a concomitant reactivity to MAG. A selective reactivity to sulfatide, however, is rarely found and is associated with different forms of neuropathy limiting its usefulness in the diagnosis of neuropathy.

Original languageEnglish
Pages (from-to)879-882
Number of pages4
JournalEuropean Journal of Neurology
Volume22
Issue number5
DOIs
Publication statusPublished - May 1 2015

    Fingerprint

Keywords

  • Antibodies
  • Autoimmunity
  • IgM
  • Neuropathy
  • Sulfatide

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this